Eli Lilly (LLY)
Develops cardiometabolic, cancer, immunology, and neuroscience medicines led by tirzepatide.
Something off on this page? Send us feedback.
Develops prescription medicines for cardiometabolic disease, cancer, immune disorders, and neuroscience, earning revenue mainly from global product sales. Mounjaro and Zepbound drive most revenue, tying results to tirzepatide demand, manufacturing capacity, payer coverage, pricing, patent protection, and regulatory approvals.
Develops and commercializes prescription medicines across cardiometabolic health, oncology, immunology, and neuroscience. Mounjaro and Zepbound, two brands for tirzepatide, anchor diabetes and obesity care; Foundayo adds an oral obesity treatment. Verzenio, Jaypirca, Taltz, Ebglyss, Omvoh, Emgality, and Kisunla extend the portfolio into cancer, immune disorders, migraine, and Alzheimer's disease.
Combines internal discovery and clinical development with licensing and acquisitions, then manufactures and distributes products through facilities in the United States, Europe, and Asia. Medicines are sold in about 90 countries, while the United States supplies most revenue.
Revenue is concentrated in Mounjaro and Zepbound. Commercial performance depends on regulatory approvals, patent protection, payer coverage and pricing, and reliable manufacturing capacity; U.S. distribution is also concentrated among a small group of large wholesalers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | Guggenheim | Reiterate | Rating: —Target: $1,273 | Target: $1,284 |
| Sep 15, 2026 | Berenberg Bank | Target | Target: $1,135 | Target: $1,400 |
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $1,251 | Target: $940 |
| Sep 1, 2026 | BMO Capital | Upgrade | ||
| Aug 7, 2026 | UBS | Target | Target: $1,425 | Target: $1,376 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.95B · Total debt $54.91B · Total assets $142.28B · Shareholders' equity $33.88B
- Revenue
- $22.97B
- Operating income
- $12.46B
- Net income
- $7.10B
HistoryDividendAnnual yield
| Institutions | 84.27% | 793.31M shares | |
|---|---|---|---|
| 4,791 holders · as of Jun 30, 2026 | |||
| Insiders | 0.14% | 1.30M shares | |
| 27 holders · as of Sep 11, 2026 | |||
| Strategic holders | 5.51% | 51.89M shares | |
| 1 holder · as of Feb 11, 2022 | |||
| Other | 10.08% | 94.86M shares | |
| remainder | |||
941.36M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Lilly Endowment IncInstitution | 9.60% | 90.38M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.17% | 67.54M | as of Jun 30, 2026 |
PRIMECAP Management CompanyInstitution | 5.79% | 54.55M | filed Apr 10, 2018 |
Vanguard Capital Management LLCInstitution | 5.69% | 53.53M | as of Jun 30, 2026 |
Inc.Strategic | 5.51% | 51.89M | filed Feb 11, 2022 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Patrik Jonsson | officer: EVP & President, LLY Int'l | −6,500 | $1,175.10 |
| Aug 10, 2026 | Donald A. Zakrowski | officer: SVP, Finance, & CAO | −2,000 | $1,185.01 |
| Aug 7, 2026 | Anat Hakim | officer: EVP, GC & Secretary | −5,000 | $1,190.00 |
| Jun 10, 2026 | Ilya Yuffa | officer: EVP&Pres, LLY USA&Global Capab | −2,500 | $1,150.77 |
| May 6, 2026 | Lilly Endowment Inc | other: Former 10% Shareholder | −15,828 | $995.36 |
- Novo Nordisk (ADR)
Primary GLP-1/GIP rival; semaglutide vs tirzepatide in obesity and diabetes.
- Merck
Keytruda dominates immuno-oncology, overlapping the Loxo-built cancer portfolio.
- AstraZeneca (ADR)
Broad oncology overlap in lung, breast, and blood cancers; SGLT-2 diabetes too.
- Novartis (ADR)
Kisqali vs Verzenio in CDK4/6 breast cancer; Pluvicto vs Lilly radioligand.
- Pfizer
Ibrance ceding CDK4/6 ground to Verzenio; next-gen atirmociclib in late trials.
- Bristol-Myers Squibb
Opdivo and Breyanzi contest Lilly's immuno-oncology and CAR-T pipeline.
- Biogen
Leqembi (lecanemab) is the only approved anti-amyloid rival to Kisunla.
- Amgen
MariTide Phase 3 program enters obesity and diabetes space as Zepbound rival.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Eli Lilly | $1,150.74 | −1.15% | $1.10T | 39.1 | 28.5 | 13.8 | +47.7% |
| Novo Nordisk (ADR) | $39.48 | −0.78% | $176.83B | 9.9 | 16.3 | 3.5 | +1.3% |
| Merck | $149.97 | +0.20% | $369.24B | 119.6 | 17.3 | 5.6 | +5.1% |
| AstraZeneca (ADR) | $168.29 | +0.14% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Novartis (ADR) | $141.39 | +0.21% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Pfizer | $27.72 | −0.18% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $62.79 | +0.18% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Biogen | $219.32 | +0.10% | $32.37B | 38.8 | 16.5 | 3.3 | +3.4% |
| Amgen | $412.00 | +4.78% | $212.19B | 24.4 | 16.8 | 5.6 | +9.7% |
| Median | 24.8 | 16.1 | 3.9 | +4.2% |